



REVISTA DE GASTROENTEROLOGÍA DE MÉXICO

www.elsevier.es/rgmx



ORIGINAL ARTICLE

A descriptive study of inflammatory bowel disease at an Egyptian tertiary care center[☆]



K.A. El-Atrebi^a, E. Taher^b, F.H. El Aguizy^b, R.M. Ali^c, A. Hegazy^d, M.M. El-Sayed^a, B. Eysa^a, A.A. El-Atreby^e, A.A. Mohammed^f, H.T. El-Bassyouni^{g,*}

^a Departamento de Medicina General y Gastroenterología, Instituto Nacional de Investigación de Hepatología y Medicina Tropical, El Cairo, Egypt

^b Departamento de Salud Pública, Universidad de El Cairo, El Cairo, Egypt

^c Departamento de Salud Pública, Instituto Nacional de Investigación de Hepatología y Medicina Tropical, El Cairo, Egypt

^d Departamento de Patología, Instituto Nacional de Investigación de Hepatología y Medicina Tropical, El Cairo, Egypt

^e Departamento de Reumatología y Rehabilitación, Instituto Nacional de Sistema Neuromotor, El Cairo, Egypt

^f Departamento de Farmacia Clínica, Instituto Nacional de Investigación de Hepatología y Medicina Tropical, El Cairo, Egypt

^g Departamento de Genética Clínica, Centro Nacional de Investigación, El Cairo, Egypt

Received 27 October 2020; accepted 8 March 2021

Available online 6 December 2021

KEYWORDS

Inflammatory bowel disease;
Ulcerative colitis;
Crohn's disease;
Descriptive

Abstract

Introduction and aims: Inflammatory bowel disease (IBD) is a group of chronic intestinal disorders that trigger prolonged inflammation of the digestive tract. Its incidence and prevalence appear to be increasing in the African population and in Egypt. The present study aims to highlight the pattern and management of IBD in Egyptian patients.

Materials and methods: Two hundred patients with IBD were assessed for ulcerative colitis (UC), through the Mayo score, and for Crohn's disease (CD), with the Crohn's disease activity index (CDAI).

Results: Median patient age was 35 years, with a predominance of females. UC was more common than CD (88% and 12%, respectively) and severity was moderate, in the majority of cases. Most UC patients had left-sided lesions, whereas ileitis was the most common finding (37.5%) in the CD patients. Proctitis was the least common finding in both diseases and Crohn's fistulizing disease was detected in 4.1% of the patients. Interestingly, peripheral arthropathy was the most common extraintestinal manifestation in the IBD patients (70%) and axial arthropathy was the least common (6%). Severe ocular or mucocutaneous involvement was very rare. Finally, biologic treatment was prescribed to 15.4% of the UC patients and 20.8% of the CD patients.

[☆] Please cite this article as: El-Atrebi KA, Taher E, El Aguizy FH, Ali RM, Hegazy A, El-Sayed MM, et al. Estudio descriptivo de la enfermedad inflamatoria intestinal en un centro de atención terciario egipcio. Rev Gastroenterol Méx. 2023;88:12–18.

* Corresponding author at: National Research Centre, El-Tahreer Street, Dokki, Cairo, Egypt. Tel.: +2 01223618884.

E-mail address: halabassyouni@yahoo.com (H.T. El-Bassyouni).

Conclusions: Although the clinical presentation of IBD in Egypt is comparable to that reported worldwide, diagnoses were found to be delayed. There were fewer cases of CD than UC, but more mild-to-moderate disease severity. The surveillance of patients with IBD must continue and awareness of the disease in the Egyptian medical community needs to increase. A national registry must be established, multicenter studies need to be conducted, and molecular diagnostics is recommended.

© 2021 Published by Masson Doyma México S.A. on behalf of Asociación Mexicana de Gastroenterología. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

PALABRAS CLAVE

Enfermedad inflamatoria intestinal;
Colitis ulcerosa crónica idiopática;
Enfermedad de Crohn;
Descriptivo

Un estudio descriptivo de la enfermedad inflamatoria intestinal en un centro de atención terciario egipcio

Resumen

Introducción y objetivos: La enfermedad inflamatoria intestinal (EII) es un grupo de trastornos intestinales crónicos que detonan una prolongada inflamación del conducto digestivo. Su prevalencia e incidencia parecen estar creciendo en la población africana y en Egipto. El presente estudio pretende señalar el patrón y manejo de la EII en pacientes egipcios.

Materiales y métodos: Doscientos pacientes con EII fueron evaluados por colitis ulcerativa crónica idiopática (CUCI), con la escala de Mayo, y por enfermedad de Crohn (EC), con el índice de actividad de la enfermedad de Crohn (*Crohn's disease activity index* [CDAI]).

Resultados: La edad promedio de los pacientes fue de 35 años, con predominancia de mujeres. La CUCI fue más común que la EC (88% y 12% respectivamente), y la gravedad fue moderada en la mayoría de los casos. La mayoría de los pacientes con CUCI tuvieron lesiones izquierdas, mientras que la ileítis fue el hallazgo más común (37.5%) en los pacientes con EC. La proctitis fue el hallazgo menos común en ambas enfermedades, y se detectó enfermedad de Crohn fistulante en 4.1% de los pacientes. De manera interesante, la artropatía periférica fue la manifestación extraintestinal más común en los pacientes con EII (70%) y la artropatía axial fue la menos común (6%). La afectación ocular grave o mucocutánea fue muy rara. Finalmente, se prescribió tratamiento biológico a 15.4% de los pacientes con CUCI y 20.8% de los pacientes con EC.

Conclusiones: Aunque la presentación clínica de la EII en Egipto es comparable a la reportada a nivel mundial, se encontró que los diagnósticos fueron tardíos. Se encontraron menos casos de EC que de CUCI, pero con mayor gravedad de leve a moderada. La vigilancia de los pacientes con EII debe continuar y el conocimiento de la enfermedad en la comunidad médica egipcia debe crecer. También es importante establecer un registro nacional, realizar estudios multicentro, y se recomienda hacer diagnósticos moleculares.

© 2021 Publicado por Masson Doyma México S.A. en nombre de Asociación Mexicana de Gastroenterología. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction and aims

Inflammatory bowel disease (IBD) is a group of chronic inflammatory conditions of the digestive system. The cause of the disease is unknown, and it commonly requires lifelong care. IBD can result in significant morbidity, but it is not generally associated with increased mortality. Most patients are able to live normal productive lives. In the long-term, up to 75% of patients with Crohn's disease (CD) and 30% of those with ulcerative colitis (UC) may require surgery¹. The incidence and prevalence of IBD appears to be increasing in the African population and in Egypt²⁻⁴.

IBD is a complex and costly disease due to its unpredictable relapsing and remitting course, complications, hospitalizations, surgeries, and the use of expensive therapies. Thus, the steady increase in the prevalence of IBD

will lead to a substantially increased burden on healthcare systems. As a lifelong disease with no cure, the compounding prevalence of IBD is due to the disparity between incidence and mortality⁵. An exaggerated immune response to antigenic stimulation by the gut microbiota, in a background of genetic susceptibility, is thought to drive the inflammatory process⁶. Environmental factors, genetic predisposition, and a dysregulated immune response may strongly increase the risk for developing IBD⁷.

The aim of the present study was to provide information on the pattern and management of IBD in Egyptian patients.

Materials and methods

The study included 200 patients with IBD recruited from the IBD Clinic at the National Hepatology and Tropical Medicine

Research Institute (NHTMRI) in Cairo, Egypt, within the time frame of December 2017 and April 2019. The study was approved by the Research Ethics Committees of the NHTMRI and the Faculty of Medicine, Cairo University.

A history of sociodemographic characteristics, including consanguinity and similarly affected family members, as well as a medical history including tonsillectomy, appendectomy, the use of oral contraceptives, smoking, and hospital admissions were collected for each patient. The clinical severity of UC and CD was determined using the Mayo score and the Crohn's disease activity index (CDAI), respectively⁸⁻¹¹ (Table 1). The following laboratory tests were carried out: complete blood count (CBC), C-reactive protein (CRP), fecal calprotectin, erythrocyte sedimentation rate (ESR), and serum bilirubin (Table 2). Patients underwent colonoscopy and tissue samples were assessed through histopathologic examination.

Statistical analysis

All the statistical analyses were performed using the SPSS version 21 for Windows (SPSS Inc) program. The Kolmogorov–Smirnov test of normality was employed to validate whether the distribution of variables followed a Gaussian pattern. The normally distributed data in the groups were expressed as mean \pm SD and the non-normally distributed data were presented as median and interquartile range (IQR). For the continuous variables, the differences between the two groups were evaluated using the Mann–Whitney U test. All tests were two-sided, and statistical significance was set at a $p < 0.05$.

Ethical considerations

Informed consent was requested from the patients to receive the treatment and participate in the research. In the case of the underage patients, their parents or guardians provided the informed consent. The present research complies with the current regulations of the Research and Ethics Committees of the NHTMRI and the Faculty of Medicine, Cairo University. The authors declare that this article contains no personal information that could identify the patients.

Results

The age of the patients included in the study ranged from 19 to 73 years (mean 31.5 ± 20), with a predominance of females (female/male ratio, 1:0.56). UC (88%) was more common than CD (12%) (Fig. 1). The sociodemographic comparison between UC and CD showed that patients with CD were significantly younger than patients with UC (median and IQR values were 31 vs 36, respectively, [$p = 0.03$]). Regarding the past history of the patients with UC and CD, more patients with CD had undergone tonsillectomy (33.3% vs 14.1%, respectively, $p = 0.01$). There was a family history of UC in 6.8% of the patients with UC, whereas none of the patients with CD had a family history of CD. The endoscopic findings are presented in Table 3. The histologic findings of the study groups were evaluated, as described

by DeRoche et al.¹² Most of the UC specimens were mild (59.7%), with the lamina propria expanded by lymphocytes and plasma cells, the surface/crypt epithelium infiltrated by neutrophils, and/or crypt abscesses in less than 50% of the crypts. In moderately active cases (25.28%), cryptitis and crypt abscesses involved more than 50% of the crypts. Severely active cases (14.9%) were defined by the presence of erosion or ulceration. Regarding the CD specimens, granuloma was found in 9.5% of the patients. The extraintestinal manifestations are presented in Table 4. The clinical severity of UC and CD was assessed by the Mayo score and the CDAI, respectively (Tables 5 and 6).

Regarding medication use in our study, steroids were employed more in the UC patients than in the CD patients. Biologic treatment was prescribed to 15.4% of the UC patients and 20.8% of the patients with CD. Finally, 12.5% of the patients were hospitalized, and 5.5% underwent surgery. A total of 2.5% of the surgical patients had stoma placement and 3% were operated on for treatment of CD.

Discussion and conclusions

In the present study, patient age ranged from 19 to 73 years (mean 31.5 ± 20), with an IQR of 17 years. Patients with CD were significantly younger than those with UC (the median and IQR values were 31 vs 36, respectively, $p = 0.03$). That finding concurs with the results of a 2016 Canadian study that included 34,819 patients, 19,713 of whom had CD and 14,683 of whom had UC. Those authors reported that patients with CD were more likely to be younger at diagnosis¹³. The age of disease onset appears to vary between patients with UC and CD¹⁴. Around 25% of patients with IBD are diagnosed within the first two decades of their lives¹⁵. However, younger populations in urban industrialized societies are usually more affected¹⁶. In our cohort, females predominated. Studies from different countries vary in their findings, regarding the association between sex and IBD. A Malaysian study on IBD reported a predominance of males, whereas an Iranian study reported a predominance of females in UC and males in CD^{17,18}. A predominance of males has also been reported in China, Japan, and Korea, in relation to CD¹⁹⁻²¹. On the other hand, the female/male ratio of UC was nearly equal in Saudi Arabia²².

In our study, IBD was more common in urban residents. That coincides with the findings of previous investigators who stated that the urbanization and industrialization of societies are associated with changes in microbial exposures, sanitation, occupations, diet, lifestyles, medications, and pollutant exposures, all of which have been implicated as potential environmental risk factors for IBD²³.

The results of our study, with a time frame of a little over two years, showed that more patients were diagnosed with UC (88%) than with CD (12%). A previous study, with a time frame of 15 years (1995–2009), was conducted in Cairo on a total of 157 patients with IBD, 135 of whom were diagnosed with UC (86%) and 22 with CD³.

The similarity of the UC/CD ratios between our study and that of the Cairo group described above, despite the differences in the time period of diagnoses and recruitment, could be due to the increasing medical and public awareness of IBD and the improvement in its diagnostic methods

Table 1 The gastrointestinal symptoms of the patients.

Symptoms	Ulcerative colitis		Crohn's disease		P
	n	%	n	%	
Abdominal pain	92	52.3	12	50	.834
Fecal urgency	54	30.7	5	20.8	.321
Blood and mucous in stools	44	25	5	20.8	.463
Constipation	37	21	7	29.2	.366
Bloating	98	55.7	13	54.2	.889
Rectal bleeding	53	30.1	9	37.5	.463
Diarrhea	72	40.9	6	25	.134
Frequency					
Mild	33	18.8	2	8.3	.289
Moderate	12	6.8	0	0.0	
Severe	19	10.8	3	12.5	
No diarrhea	112	63.6	19	79.2	

Table 2 The laboratory test results of the patients.

Laboratory tests	Ulcerative colitis Median (IQR)	Crohn's disease Median (IQR)	Normal value	p
Calprotectin, $\mu\text{g}/\text{dl}$	465 (475)	667.5 (886)	<50	.299
Hemoglobin, g/dl	12 (2)	12 (3)	11.6–16.6	.569
Leukocytes, $10^9/\text{l}$	8(4)	6.9 (4)	3.4–9.6	.517
Platelets, $10^9/\text{l}$	279 (73)	279 (92)	135–371	.467
Hematocrit, $10^9/\text{l}$	35 (7)	34 (8.7)	35.5–38.6	.899
CRP mg/l	12 (19)	24 (19)	<10	.538
ESR mm/hour	54 (92)	54 (57)	Females 0–22 Males 0–29	1.0

CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; IQR: interquartile range.




Figure 1 The percent distribution of the patients: UC (88%) was more common than CD (12%) in the present study.

in Egypt. Worldwide findings have shown comparable findings, but there was a 6-fold increase in UC in our study, whereas a 2-fold increase has been reported in Europe. Likewise, Asia and some Middle Eastern countries have shown a slight increase in UC patients. Inversely, more patients with CD than with UC have been reported in North American studies^{17,24,25}.

IBD is a complex disease whose endoscopic characterization is based on its mucosal features that aid in determining disease extent and activity. The mucosal changes are seen within a particular anatomic distribution of the colon or the small bowel. Colonoscopic evaluation of the mucosa is crucial to assessing disease activity and consequently pre-

Table 3 The endoscopic findings of the patients.

Findings	UC		CD		P
	n	%	n	%	
Extensive colitis	39	23.5	6	25	0.0
Left-sided lesions	96	57.8	6	25	
Proctitis	31	18.6	2	8.3	
Ileitis	0	0	9	37.5	
Fistulizing disease	0	0	1	4.1	

Table 4 Extraintestinal manifestations in the IBD patients.

Extraintestinal manifestations	n	%
Peripheral arthropathy	140	70
Axial arthropathy	12	6
Mucocutaneous involvement ^a	64	32
Ocular involvement ^b	40	20
Primary sclerosing cholangitis	3	1.5

^a There was one case of extensive psoriasis; the others presented with aphthous stomatitis.

^b 10% of the patients with ocular involvement had severe manifestations; the other cases had mild manifestations.

scribing the therapy targeted at particular segments of the colon²⁶.

Regarding UC, most of our patients had left-sided lesions (57.8%) and the fewest presented with proctitis (18.6%). Newly diagnosed cases of UC have been reported to be confined to the rectum and the rectosigmoid colon^{27,28}. In another study, 20–30% of patients with UC had left-sided colitis²⁶. In our patients with CD, ileitis was the most common (37.5%) presentation, followed by extensive colitis and left-sided lesions (25%), whereas proctitis and fistulizing disease were the least common (8.3% and 4.1%, respectively). In a previous study, inspection of the terminal ileum was emphasized as being sufficient to confirm the diagnosis of CD in most patients^{29,30}.

According to the Mayo score, the majority of our UC patients presented with a moderate degree of activity, whereas severe activity was the least common. The endoscopic results of a multicenter European study revealed that 44.3% of patients had moderate-to-severe activity³¹. Most of the CD patients in our study had moderate activity (60%). Only one case presented with severe activity (6.7%), according to the CDAI. Likewise, previous research has shown that the majority of patients have mild-to-moderate activity^{24,32}.

In our study, the patients with UC had a higher incidence of diarrhea (40.9%) than the patients in the CD group (25%). Previous investigations reported an increase in the frequency of loose/watery bowel movements in UC (80%), compared with CD (60.3%), which could be related to environmental factors or the type of diet in the different populations^{33,34}. Furthermore, the frequency of diarrhea in IBD patients differs, depending on the site and magnitude of intestinal inflammation.

Consequently, understanding the molecular mechanisms leading to diarrhea in IBD is important for proper diagnosis and management³⁵. High calprotectin levels seen in CD could

Table 5 Mayo scores of patients with ulcerative colitis.

Severity	Frequency	%
Remission	20	14.5
Mild activity	42	30.4
Moderate activity	72	52.2
Severe activity	4	2.9
Total	138	100

Table 6 Crohn's disease activity index (CDAI) score.

Severity	Frequency	%
Remission	2	13.3
Mild activity	3	20
Moderate activity	9	60
Severe activity	1	6.7
Total	15	100

be due to colonic involvement or they could be an indication of high recurrence risk or poor treatment efficiency³⁶.

Steroid use in the patients in the present study was slightly higher in the UC patients than in the CD patients, coinciding with the results of a previous study, in which excess steroid exposure was more common in patients with UC, compared with patients with CD³⁷. Biologic treatment was prescribed to 15.4% of our UC patients, and 20.8% of those with CD. Other studies describe a higher prescription of biologic treatments for CD vs UC^{38,39}. Our results could reflect the national protocol that approves one or two cycles of conventional therapy, followed by laboratory and colonoscopy assessment for a period ranging from 6 months to one year, before switching to biologic treatment.

The prevalence of IBD-related extraintestinal manifestations (EIMs) remains controversial, with various estimates dependent on geographic region, definitions, and exclusion criteria. EIMs most often affect the joints (peripheral and axial arthropathy), skin (erythema nodosum, pyoderma gangrenosum, aphthous stomatitis, and psoriasis), eyes (episcleritis, uveitis), and the hepatobiliary tract (primary sclerosing cholangitis)⁴⁰. In a cohort of IBD patients with EIMs, approximately 63% presented with one manifestation and 27% presented with two⁴¹.

Peripheral arthropathy was the most common EIM (70%) in our study. Comparably, previous studies described peripheral arthropathies as the most common EIM^{40,42}. Axial arthropathy occurs in 3–5% of patients with IBD^{42,43}. In the present study, axial arthropathy was the least common EIM

(6%). Thirty-two percent of our patients experienced mucocutaneous involvement. One case suffered from extensive psoriasis and the others presented with aphthous stomatitis. Approximately 16% of our patients had mucocutaneous EIMs⁴³.

In conclusion, even though the clinical presentation of IBD in Egypt is comparable to that reported worldwide, the diagnoses in our study patients were delayed, with lower numbers of CD, but more mild-to-moderate disease severity. The surveillance of patients with IBD must continue and awareness of the disease in the Egyptian medical community needs to increase. A national registry must be established, multicenter studies need to be conducted, and molecular diagnostics is recommended.

Financial disclosure

No specific grants were received from public sector agencies, the business sector, or non-profit organizations in relation to this study.

Authorship

Kamal A. El-Atrebi: concept, drafting, and design of the study, Eman Taher: data analysis and interpretation, Fayrouz Hamed El Aguizy: data acquisition and interpretation, Rahma M. Ali: participated in the study concept and design, Aza Hegazy: performed the pathologic studies, Mohammed M. El-Sayed: data analysis and interpretation, Basem Eysa: examination of patients and interpretation of data, Ahmed A. El-Atreby: examination of patients and interpretation of data, Aliaa A. Mohammed: data analysis and interpretation, Hala T. El-Bassyouni: drafting and revision the manuscript.

Conflict of interest

The authors declare that there is no conflict of interest.

References

1. DuBois KE, Beets M, Blake C, et al. Meta-analysis of dietary intervention effects in Crohn's disease and ulcerative colitis. *Gastroenterology*. 2019;156:S14.
2. Agoda-Koussema LK, Anoukoum T, Djibril AM, et al. Ulcerative colitis: a case in Togo. *Med Sante Trop*. 2012;22:79–81.
3. Esmat S, El Nady M, Elfekki M, et al. Epidemiological and clinical characteristics of inflammatory bowel diseases in Cairo, Egypt. *World J Gastroenterol*. 2014;20:814–21.
4. El-Atrebi KA, El-Bassyouni HT. Inflammatory bowel disease (IBD) unit: an Egyptian experience. *Gastroenterol Dig Syst*. 2018;5:1.
5. Coward S, Clement F, Benchimol EI, et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. *Gastroenterology*. 2019;156:1345–530000.
6. Khor B, Gardet A, Xavier JR. Genetics and pathogenesis of inflammatory bowel disease. *Nature*. 2011;474:307–17.
7. Ananthakrishnan AN. Epidemiology and risk factors for IBD. *Nat Rev Gastroenterol Hepatol*. 2015;12:205–17.
8. Abegunde AT, Muhammad BH, Bhatti O, et al. Environmental risk factors for inflammatory bowel diseases: evidence based literature review. *World J Gastroenterol*. 2016;22:6296–317.

9. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. *N Engl J Med*. 1987;317:1625–9.
10. Rutgeerts P, Vermeire S, Assche VG. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? *Gut*. 2007;56:453–5.
11. Best WR, Beckett JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. *Gastroenterology*. 1976;70:439–44.
12. DeRoche TC, Xiao SY, Liu X. Histological evaluation in ulcerative colitis. *Gastroenterol Rep (Oxf)*. 2014;2:178–92.
13. Cleynen I, Boucher G, Jostins L, et al. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. *Lancet*. 2016;387:156–67.
14. Benchimol EI, Seow CH, Otley AR, et al. Budesonide for maintenance of remission in Crohn's disease. *Cochrane Database Syst Rev*. 2009;1:CD002913.
15. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology*. 2012;142:46–54.e42, quiz e30.
16. Kim KY, Lee EJ, Kim JW, et al. Higher morbidity of monogenic inflammatory bowel disease compared to the adolescent onset inflammatory bowel disease. *Pediatr Gastroenterol Hepatol Nutr*. 2018;21:34–42.
17. Mokhtar NM, Nawawi KNM, Verasingam J, et al. A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary Centre, Kuala Lumpur, Malaysia. *BMC Public Health*. 2019;19:550.
18. Safarpour AR, Hosseini SV, Mehrabani D. Epidemiology of inflammatory bowel diseases in Iran and Asia; a mini review. *Iran J Med Sci*. 2013;38:140.
19. Leong RW, Lau JY, Sung JJ. The epidemiology and phenotype of Crohn's disease in the Chinese population. *Inflamm Bowel Dis*. 2004;646:10–51.
20. Yao T, Matsui T, Hiwatashi N. Crohn's disease in Japan: diagnostic criteria and epidemiology. *Dis Colon Rectum*. 2000;43:S85–93, <http://dx.doi.org/10.1007/BF02237231>.
21. Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. *Inflamm Bowel Dis*. 2010;14:542–9.
22. Al-Ghamdi AS, Al-Mofleh IA, Al-Rashed RS, et al. Epidemiology and outcome of Crohn's disease in a teaching hospital in Riyadh. *World J Gastroenterol*. 2004;10:1341–2.
23. Charlebois A, Rosenfeld G, Bressler B. The impact of dietary interventions on the symptoms of inflammatory bowel disease: a systematic review. *Crit Rev Food Sci Nutr*. 2016;56:1370–8.
24. Le Berre C, Peyrin-Biroulet L, Buisson A, et al. Impact of inflammatory bowel diseases on working life: a French nationwide survey. *Dig Liver Dis*. 2019;51:961–6.
25. Asakura K, Nishiwaki Y, Inoue N, et al. Prevalence of ulcerative colitis and Crohn's disease in Japan. *J Gastroenterol*. 2009;44:659–65.
26. Malekzadeh MM, Vahedi H, Gohari K, et al. Emerging epidemic of inflammatory bowel disease in a middle-income country: a nation-wide study from Iran. *Arch Iran Med*. 2016;19:1–14.
27. Paine ER. Colonoscopic evaluation in ulcerative colitis. *Gastroenterol Rep (Oxf)*. 2014;2:161–8.
28. Miner PB. Clinical features, course, laboratory findings, and complications in ulcerative colitis. In: Kirsner J, editor. *Inflammatory bowel disease*. Philadelphia: WB Saunders Company; 2000. p. 299–304.
29. Langholz E. Current trends in inflammatory bowel disease: the natural history. *Therap Adv Gastroenterol*. 2010;3:77–86.

30. Tontini GE, Vecchi M, Pastorelli L, et al. Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. *World J Gastroenterol.* 2015;21:21.
31. Ye L, Lin Z, Liu J, et al. Vitamin D deficiency is associated with endoscopic severity in patients with Crohn's disease. *Gastroenterol Res Pract.* 2017;2017.
32. Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tumor necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. *Gut.* 2011;60:930–6.
33. Sjöberg D, Holmström T, Larsson M, et al. Incidence and clinical course of Crohn's disease during the first year – results from the IBD Cohort of the Uppsala Region (ICURE) of Sweden 2005-2009. *J Crohns Colitis.* 2014;8:215–22.
34. Perler BK, Ungaro R, Baird G, et al. Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inception cohort. *BMC Gastroenterol.* 2019;19:47.
35. Anbazhagan AN, Priyamvada S, Alrefai WA, et al. Pathophysiology of IBD associated diarrhea. *Tissue Barriers.* 2018;6:e1463897, <http://dx.doi.org/10.1080/21688370.2018.1463897>.
36. Knyazev OV, Kagramanova AV, Korneeva IA, et al. The use of fecal calprotectin in monitoring activity of inflammatory bowel diseases. *Ter Arkh.* 2019;91:53–61.
37. Asscher V, Provoost N, Meijer L, et al. P562 Treatment of older inflammatory bowel disease patients; steroid use and escalation to steroid sparing therapy. *J Crohns Colitis.* 2019;13:395.
38. Brady JE, Stott-Miller M, Mu G, et al. Treatment patterns and sequencing in patients with inflammatory bowel disease. *Clin Ther.* 2018;40:1509–21.e5.
39. Lightner AL, McKenna NP, Alsughayer A, et al. Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients. *Pediatr Surg.* 2019;54:2162–5.
40. Garber A, Regueiro M. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, etiopathogenesis, and management. *Curr Gastroenterol Rep.* 2019;21:31.
41. Ferreira SDC, Oliveira BBMD, Morsoletto AM. Extraintestinal manifestations of inflammatory bowel disease: clinical aspects and pathogenesis. *J Gastroenterol Dig Dis.* 2018;3:4–11.
42. Vavricka SR, Rogler G, Gantenbein C, et al. Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss inflammatory bowel disease cohort. *Inflamm Bowel Dis.* 2015;21:1794–800.
43. Yang BR, Choi NK, Kim MS, et al. Prevalence of extraintestinal manifestations in Korean inflammatory bowel disease patients. *PLoS One.* 2018;13:e0200363.